Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Developments research found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://abbac427hbm2.iyublog.com/profile